



**NYACP Member Immunization Survey Results**  
**Data Collection Timeframe 12/1/2019 – 1/31/2020**  
**Report Date: March 2, 2020**

**BACKGROUND**

On September 17, 2019, the New York Chapter of the American College of Physicians’ Health and Public Policy Committee established an Immunization Task Force to survey members about the types of immunizations they stock in their offices for patient care. The Immunization Task Force members consulted the “Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2020” published by the Centers for Disease Control and Prevention. The survey created by the Task Force listed each vaccine included in the CDC’s schedule as a separate check-off box, and asked members to comment on why they do not stock the vaccine if it was one not kept in their office. General practice demographic data was also collected.


The survey was distributed to 7,321 NYACP members in the December 12, 2019 *Your Chapter in Action* newsletter, and as a separate member drive-out to 7,272 members through VoterVoice on January 15, 2020. In addition, the January 2020 NYACP advocacy intern contacted individual members of the NYACP Council and Board to request their participation as a survey respondent. When the survey closed on January 31, 2020, 169 members had completed the survey.

Support for this survey was generously provided by Pfizer. The results are limited due to the relatively low number of respondents (2.3%), and the unknown correlation between immunization practices of physicians working for large, institutional healthcare providers, versus small to medium size private practices. Some respondents who do not work in positions with direct patient contact completed the survey, thereby potentially skewing the percentage of respondents reporting that they do not stock particular vaccines in their offices.

**SUMMARY OF OUTCOMES**

The conclusions of the survey suggest that, overall, respondent-physicians stock the vaccines that their patients need on a routine basis, and do not stock the vaccines that their patients generally do not need. For vaccines that are reimbursed through Medicare Part D, physicians send patients to pharmacies or other facilities. To date, the drug included in the “Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2020” that falls into the Medicare Part D category is the vaccine for shingles.

Which of the following best describes your practice environment?



## Which vaccines do you have available for patients in your office?

### Haemophilus influenzae type b

44 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 16.4% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Haemophilus influenzae type b	60
<b>Not needed for population</b>	39
<b>Cost</b>	3
<b>Infrequent use</b>	14
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	0
<b>Not available to practice</b>	0
<b>Patient referred to other specialists, county or pharmacy when needed</b>	1
<b>Ordered if needed</b>	3
<b>Other</b>	0

### Hepatitis A

121 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 71.6% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Hepatitis A Vaccine	14
<b>Not needed for population</b>	3
<b>Cost</b>	0
<b>Infrequent use</b>	6
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	0
<b>Not available to practice</b>	2
<b>Patient referred to other specialists, county or pharmacy when needed</b>	1
<b>Ordered if needed</b>	2
<b>Other</b>	0

### Hepatitis B

131 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 77.5% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Hepatitis B Vaccine	10
<b>Not needed for population</b>	1
<b>Cost</b>	0
<b>Infrequent use</b>	5
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	0
<b>Not available to practice</b>	0
<b>Patient referred to other specialists, county or pharmacy when needed</b>	2
<b>Ordered if needed</b>	1
<b>Other</b>	1

### Human Papillomavirus

101 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 59.8% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Human Papillomavirus Vaccine	27
<b>Not needed for population</b>	14
<b>Cost</b>	2
<b>Infrequent use</b>	0
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	0
<b>Not available to practice</b>	3
<b>Patient referred to other specialists, county or pharmacy when needed</b>	4

<b>Ordered if needed</b>	3
<b>Other</b>	1

### **Influenza (inactivated)**

133 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 78.7% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

<b># of Comments Received for Not Stocking Influenza (inactivated) Vaccine</b>	<b>5</b>
<b>Not needed for population</b>	0
<b>Cost</b>	1
<b>Infrequent use</b>	1
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	1
<b>Not available to practice</b>	0
<b>Patient referred to other specialists, county or pharmacy when needed</b>	0
<b>Ordered if needed</b>	0
<b>Other</b>	2

### **Influenza (live attenuated)**

26 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 15.4% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

<b># of Comments Received for Not Stocking Influenza (live attenuated) Vaccine</b>	<b>53</b>
<b>Not needed for population</b>	17
<b>Cost</b>	1
<b>Infrequent use</b>	4
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	2
<b>Not available to practice</b>	0
<b>Patient referred to other specialists, county or pharmacy when needed</b>	0
<b>Ordered if needed</b>	1
<b>Other – <i>The most common response was that the vaccine was not stocked because it was not recommended</i></b>	28

### **Influenza (recombinant)**

72 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 42.6% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Influenza (recombinant) Vaccine	17
<b>Not needed for population</b>	6
<b>Cost</b>	3
<b>Infrequent use</b>	0
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	2
<b>Not available to practice</b>	0
<b>Patient referred to other specialists, county or county when needed</b>	0
<b>Ordered if needed</b>	0
<b>Other</b>	6

### Measles, mumps & rubella

0 of 169 respondents said that they keep a supply of this vaccine in their office.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Measles, Mumps & Rubella Vaccine	17
<b>Not needed for population</b>	4
<b>Cost</b>	1
<b>Infrequent use</b>	5
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	0
<b>Not available to practice</b>	0
<b>Patient referred to other specialists, county or pharmacy when needed</b>	1
<b>Ordered if needed</b>	4
<b>Other</b>	2

### Meningococcal serogroups A, C, W, Y

0 of 169 respondents said that they keep a supply of this vaccine in their office.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Meningococcal serogroups A,C,W, Y Vaccine	32
<b>Not needed for population</b>	15
<b>Cost</b>	4
<b>Infrequent use</b>	3
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	2
<b>Not available to practice</b>	1
<b>Patient referred to other specialists, county or pharmacy when needed</b>	1
<b>Ordered if needed</b>	5
<b>Other</b>	1

### **Meningococcal serogroup B**

8 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 4.7% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Meningococcal serogroup B Vaccine	35
<b>Not needed for population</b>	9
<b>Cost</b>	3
<b>Infrequent use</b>	8
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	3
<b>Not available to practice</b>	0
<b>Patient referred to other specialists, county or pharmacy when needed</b>	1
<b>Ordered if needed</b>	5
<b>Other</b>	6

### **Pneumococcal 13-valent conjugate**

141 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 83.4% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Pneumococcal 13-valent conjugate Vaccine	11
<b>Not needed for population</b>	2
<b>Cost</b>	5
<b>Infrequent use</b>	0
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	0
<b>Not available to practice</b>	0
<b>Patient referred to other specialists, county or pharmacy when needed</b>	2
<b>Ordered if needed</b>	1
<b>Other</b>	1

### **Pneumococcal 23-valent polysaccharide**

146 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 86.4% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Pneumococcal 23-valent polysaccharide Vaccine	11
<b>Not needed for population</b>	2
<b>Cost</b>	5
<b>Infrequent use</b>	0
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	0
<b>Not available to practice</b>	0
<b>Patient referred to other specialists, county or pharmacy when needed</b>	2
<b>Ordered if needed</b>	1
<b>Other</b>	1

### Tetanus and Diphtheria Toxoids

102 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 60.4% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Tetanus and Diphtheria Toxoids Vaccine	14
<b>Not needed for population</b>	4
<b>Cost</b>	1
<b>Infrequent use</b>	1
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	0
<b>Not available to practice</b>	0
<b>Patient referred to other specialists or county when needed</b>	0
<b>Ordered if needed</b>	1
<b>Other</b>	7

### Tetanus and Diphtheria Toxoids and Acellular Pertussis

145 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 85.8% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Tetanus and Diphtheria Toxoids and Acellular Pertussis Vaccine	7
<b>Not needed for population</b>	2
<b>Cost</b>	1
<b>Infrequent use</b>	2
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	0
<b>Not available to practice</b>	0
<b>Patient referred to other specialists when or county needed or</b>	0

<b>Ordered if needed</b>	1
<b>Other</b>	1

### Varicella

87 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 51.4% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Varicella Vaccine	30
<b>Not needed for population</b>	14
<b>Cost</b>	6
<b>Infrequent use</b>	2
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	1
<b>Not available to practice</b>	0
<b>Patient referred to other specialists or county when needed or county</b>	0
<b>Ordered if needed</b>	2
<b>Other</b>	5

### Zoster (recombinant)

87 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 49.7% of respondents.

Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Zoster (recombinant) Vaccine	44
<b>Not needed for population</b>	3
<b>Cost</b>	17
<b>Infrequent use</b>	2
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	4
<b>Not available to practice</b>	2
<b>Patient referred to other specialists or county when needed</b>	0
<b>Ordered if needed</b>	0
<b>Other</b>	7
<b>***Not able to Bill for this Vaccine***</b>	9

### Zoster (live)

28 of 169 respondents said that they keep a supply of this vaccine in their office.

This represents 16.6% of respondents.



Respondents who said that they did not have this vaccine available in their practice location were invited to comment on the reason why. Below is a summary of these replies.

# of Comments Received for Not Stocking Zoster (live) Vaccine	70
<b>Not needed for population</b>	3
<b>Cost</b>	7
<b>Infrequent use</b>	6
<b>Policy restrictions (practice of hospital limits on what can be ordered)</b>	3
<b>Not available to practice</b>	0
<b>Patient referred to other specialists or county when needed</b>	0
<b>Ordered if needed</b>	1
<b>Other</b>	13
<b>***No Longer Recommended due to Alternative Available***</b>	37